title: Community pharmacists' knowledge and perceptions about adverse drug reactions and barriers towards their reporting in Eastern region, Alahsa, Saudi Arabia.
abstract: OBJECTIVE
  The present study aims to analyze community pharmacists' current knowledge and perceived barriers to adverse drug reaction (ADR) reporting systems in the Eastern region, Alahsa, Saudi Arabia.
  
  
  METHODS
  A cross-sectional study was planned from 1 June 2012 to 15 July 2012 among the community pharmacies in the Eastern region, Alahsa. A total of 70 community pharmacists were approached using a cluster sampling method. A self-administered, 28-item questionnaire was used to attain the objectives of the study. Data analysis was done using Statistical Package for Social Science version 13. Relative index ranking was used to identify the top five barriers to the ADR reporting process.
  
  
  RESULTS
  Response to the survey was 71.43%. In terms of knowledge about ADRs, very few (four, 8.0%) pharmacists were unable to differentiate between the right and wrong definition of ADRs. About 42 (84.0%) pharmacists mentioned that patients often report adverse events. However, 45 (90.0%) were not aware of the ADR reporting system in Saudi Arabia. A deficient professional environment was the main barrier to the ADR reporting process. In addition, unavailability of the reporting forms and poor understanding of the reporting process were common barriers to the reporting process.
  
  
  CONCLUSIONS
  Most of the community pharmacists were unaware of the ADR reporting system in Saudi Arabia. Logistic issues were the main barriers to the ADR reporting process.
authors.affiliation: Department of Pharmacy Practice, College of Clinical Pharmacy, King Faisal University, Alahsa, 31982 Saudi Arabia.
authors.forename: Tahir M
authors.initials: TM
authors.lastname: Khan
keywords: Saudi Arabia; adverse drug reaction; barriers; community pharmacists; knowledge
references.citation: Saudi Pharm J. 2013 Jan;21(1):13-8
references.pmid: 23960815
references.citation: JAMA. 1991 Nov 27;266(20):2847-51
references.pmid: 1942452
references.citation: Proc Annu Symp Comput Appl Med Care. 1991;:23-7
references.pmid: 1807594
references.citation: Ir J Med Sci. 1999 Oct-Dec;168(4):257-61
references.pmid: 10624366
references.citation: Ann Pharmacother. 1994 Dec;28(12):1400-3
references.pmid: 7696734
references.citation: Eur J Clin Pharmacol. 2000 Dec;56(9-10):729-32
references.pmid: 11214784
references.citation: BMJ. 2004 Jul 3;329(7456):15-9
references.pmid: 15231615
references.citation: Pharmacoepidemiol Drug Saf. 2004 Jul;13(7):457-64
references.pmid: 15269929
references.citation: Pharmacoepidemiol Drug Saf. 2002 Jan-Feb;11(1):65-72
references.pmid: 11998554
references.citation: Br J Clin Pharmacol. 1999 Oct;48(4):623-7
references.pmid: 10583035
references.citation: Pharm World Sci. 2008 Oct;30(5):556-62
references.pmid: 18350373
references.citation: Am J Med. 2000 Aug 1;109(2):122-30
references.pmid: 10967153
references.citation: Chin Med J (Engl). 2004 Jun;117(6):856-61
references.pmid: 15198887
references.citation: Drug Saf. 2004;27(12):857-70
references.pmid: 15366974
references.citation: Lancet. 2003 Apr 19;361(9366):1347-8
references.pmid: 12711472
references.citation: BMJ. 1998 Apr 25;316(7140):1295-8
references.pmid: 9554902
references.citation: Ned Tijdschr Geneeskd. 2005 Mar 5;149(10):529-33
references.pmid: 15782689
references.citation: Br J Clin Pharmacol. 1992 Nov;34(5):421-6
references.pmid: 1467137
references.citation: Ann Pharmacother. 1995 Apr;29(4):365-9
references.pmid: 7633012
references.citation: Lancet. 2002 Nov 9;360(9344):1435
references.pmid: 12433504
references.citation: Am J Health Syst Pharm. 2007 Apr 15;64(8):842-9
references.pmid: 17420201
references.citation: Br J Clin Pharmacol. 1995 Mar;39(3):223-6
references.pmid: 7619660
references.citation: Eur J Clin Pharmacol. 1997;52(6):423-7
references.pmid: 9342576